.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
Novartis
Cipla
Julphar
Accenture
Medtronic
Deloitte
Fish and Richardson
Fuji
Chubb

Generated: September 19, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Summary for Patent: ► Subscribe

Title:Use of an anti-Ang2 antibody
Abstract: A method of preventing or treating cancer using an anti-Ang2 antibody or an antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang2) and complexes to a Tie2 receptor while bound with Ang2.
Inventor(s): Kim; Kyung Eun (Yongin-si, KR), Han; Sang Yeul (Yongin-si, KR), Koh; Gou Young (Daejeon, KR), Lee; Hyo Seon (Hwaseong-si, KR), Kim; Chan (Seoul, KR)
Assignee: SAMSUNG ELECTRONICS CO., LTD. (Suwon-Si, KR) KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (Daejeon, KR)
Application Number:14/446,199
Patent Claims:1. A method of enhancing the efficacy of an anticancer agent, comprising administering an anti-cancer agent and an anti-Ang2 antibody or an antigen-binding fragment thereof to a subject in need thereof, wherein the anti-Ang2 antibody or the antigen-binding fragment thereof specifically binds to Ang2 and forms a complex with a Tie2 receptor via Ang2; and the anti-Ang2 antibody or an antigen-binding fragment thereof binds to Q418, P419 or a combination of Q418 and P419 in human Ang2 of SEQ ID NO: 11; or binds to 2 to 20 contiguous amino acid residues of SEQ ID NO: 11 including Q418, P419 or a combination of Q418 and P419, wherein the anti-Ang2 antibody or an antigen-binding fragment thereof comprises: a first heavy chain complementarity determining region (CDR-H1) comprising the amino acid sequence of SEQ ID NO: 1, a second heavy chain complementarity determining region (CDR-H2) comprising the amino acid sequence of SEQ ID NO: 2, a third heavy chain complementarity determining region (CDR-H3) comprising the amino acid sequence of SEQ ID NO: 3, a first light chain complementarity determining region (CDR-L1) comprising the amino acid sequence of SEQ ID NO: 4, a second light chain complementarity determining region (CDR-L2) comprising the amino acid sequence of SEQ ID NO: 5, and a third light chain complementarity determining region (CDR-L3) comprising the amino acid sequence of SEQ ID NO: 6.

2. The method of claim 1, wherein the anti-Ang2 antibody or an antigen-binding fragment thereof increases the activity of Tie2 by increasing phosphorylation of Tie2 receptor.

3. The method of claim 1, wherein the anti-Ang2 antibody or an antigen-binding fragment thereof increases phosphorylation of at least one protein selected from the group consisting of Akt, eNOS, and MAPK1 42/44.

4. The method of claim 1, wherein the anti-Ang2 antibody or an antigen-binding fragment thereof comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 9.

5. The method of claim 1, wherein the anti-Ang2 antibody or an antigen-binding fragment thereof is produced from a hybridoma deposited with accession number KCLRF-BP-00295.

6. The method of claim 1, further comprising administering Ang2 to the subject.

7. The method of claim 1, wherein the anticancer agent is at least one selected from the group consisting of cisplatin, carboplatin, oxaliplatin, mechlorethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, thiotepa, altretamine, procarbazine, busulfan, carmustine, lomustine, dacarbazine, fluorouracil (5-FU), capecitabine, cytarabine, gemcitabine, methotrexate (MTX), mercaptopurine (6-MP), vinblastine, vincristine, vinorelvine, paclitaxel, docetaxel, etoposide topotecan, irinotecan, dactinomycin, doxorubicin, daunorubicin, mitomycin, bleomycin, imatinib, trastuzumab, cetuximab, gefitinib, erlotinib, bevacizumab, sunitinib, sorafenib, cabozantinib, pazopanib, regorafenib, vandetanib, ziv-afilibercept, prednisone, and 6-thioguanine (6-TG).

8. The method of claim 1, wherein the anti-cancer agent and anti-Ang2 antibody are administered simultaneously or sequentially in any order.

Summary for Patent: ► Subscribe

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
South Korea10-2013-0112089Sep 17, 2013

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Inventors Patent Expiration Status Orphan Source
Genentech
HERCEPTIN
trastuzumab
VIAL; INTRAVENOUS1037920011998-09-25► Subscribe SAMSUNG ELECTRONICS CO., LTD. (Suwon-Si, KR) KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (Daejeon, KR) Kim; Kyung Eun (Yongin-si, KR), Han; Sang Yeul (Yongin-si, KR), Koh; Gou Young (Daejeon, KR), Lee; Hyo Seon (Hwaseong-si, KR), Kim; Chan (Seoul, KR) ► SubscribeRXOrphansearch
Imclone
ERBITUX
cetuximab
VIAL; INTRAVENOUS1250840012004-06-18► Subscribe SAMSUNG ELECTRONICS CO., LTD. (Suwon-Si, KR) KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (Daejeon, KR) Kim; Kyung Eun (Yongin-si, KR), Han; Sang Yeul (Yongin-si, KR), Koh; Gou Young (Daejeon, KR), Lee; Hyo Seon (Hwaseong-si, KR), Kim; Chan (Seoul, KR) ► SubscribeRXOrphansearch
Genentech
AVASTIN
bevacizumab
VIAL; INTRAVENOUS1250850012004-02-26► Subscribe SAMSUNG ELECTRONICS CO., LTD. (Suwon-Si, KR) KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (Daejeon, KR) Kim; Kyung Eun (Yongin-si, KR), Han; Sang Yeul (Yongin-si, KR), Koh; Gou Young (Daejeon, KR), Lee; Hyo Seon (Hwaseong-si, KR), Kim; Chan (Seoul, KR) ► SubscribeRXsearch
Genentech
AVASTIN
bevacizumab
VIAL; INTRAVENOUS1250850022004-02-26► Subscribe SAMSUNG ELECTRONICS CO., LTD. (Suwon-Si, KR) KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (Daejeon, KR) Kim; Kyung Eun (Yongin-si, KR), Han; Sang Yeul (Yongin-si, KR), Koh; Gou Young (Daejeon, KR), Lee; Hyo Seon (Hwaseong-si, KR), Kim; Chan (Seoul, KR) ► SubscribeRXsearch
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Publication Date
European Patent Office2848631Mar 18, 2015
South Korea20150032075Mar 25, 2015
United States of America2015079112Mar 19, 2015
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.


« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Julphar
Fish and Richardson
Chubb
Teva
Johnson and Johnson
Dow
Boehringer Ingelheim
Novartis
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot